News Release

Yamanouchi Pharmaceutical Co., Ltd.

Yamanouchi Receives Approval for Vesicare from US FDA for the Treatment of Overactive Bladder

November 22, 2004

Tokyo, Japan - November 22, 2004 - Yamanouchi Pharmaceutical Co., Ltd. (president: Toichi Takenaka) announced that it received approval from the Food and Drug Administration (FDA) for the treatment of overactive bladder with symptoms of urgency, frequency and urge incontinence for Vesicare(generic name: solifenacin succinate). Once-daily Vesicareis a global product of Yamanouchi, and this approval follows the one obtained in Europe where the product was launched in August.

At present, Yamanouchi is constructing a marketing system of its own in the US. Vesicare will be marketed by its wholly owned US subsidiary, Yamanouchi Pharma America, Inc (YPA: Paramus, NJ) as the first product Yamanouchi will independently market in the US. It will be copromoted by the US subsidiary of GlaxoSmithKline of the UK. Launching is scheduled for January 2005.

Vesicare is an anticholinergic that works to selectively block the muscarinic (nerve) receptors, causing the detrusor muscle to relax, thereby reducing overactive bladder symptoms of urgency, frequency and urge incontinence. While overactive bladder affects an estimated 17 to 20 million men and women in the United States, few understand that it is a treatable condition. Many mistakenly believe this is a natural part of aging, are embarrassed to discuss it, or believe there is no treatment option available. Therefore, patients gradually develop coping behaviors to manage their symptoms. These coping mechanisms include restricting fluids, carrying extra clothing, "mapping" bathroom locations, or even choosing not to leave the house.

In Japan, an NDA for Vesicare was filed with the Ministry of Health, Labor and Welfare in August (development code No.: YM905). Yamanouchi plans to launch it onto the global market (Japan, US, and Europe) in order to expand its market as quickly as possible. By adding this product to Harnal (tamsulosin), a drug for the treatment of functional symptoms of benign prostatic hyperplasia (BPH) currently marketed in more than 60 countries around the world, Yamanouchi plans to further strengthen its presence in the market for urological drugs.